Mechanisms of cisplatin nephrotoxicity

Toxins

Volumn 2, Issue 11, 2010, Pages 2490-2518

  Miller, Ronald P ^a   Tadagavadi, Raghu K ^a   Ramesh, Ganesan ^a   Reeves, William Brian ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Cisplatin; Cytokines; Dendritic cells; Inflammation; Kidney injury; Nephrotoxicity; Toll like receptors

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; CASPASE 2; CASPASE 8; CATALASE; CIMETIDINE; CISPLATIN; CREATININE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; CYTOKINE; DIMESNA; FUROSEMIDE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MANNITOL; METFORMIN; NITROGEN; ORGANIC CATION TRANSPORTER 2; PROTEIN BAX; SELENIUM; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNINDEXED DRUG; UREA; VERAPAMIL;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; APOPTOSIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRESS; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DNA DAMAGE; DNA POLYMORPHISM; DOSE RESPONSE; DOWN REGULATION; DRUG ACCUMULATION; DRUG DNA BINDING; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSFORMATION; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HISTONE ACETYLATION; HUMAN; HYPOMAGNESEMIA; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; MACROPHAGE; MITOSIS INHIBITION; NEPHRITIS; NEPHROTOXICITY; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; UREA NITROGEN BLOOD LEVEL; UREMIA; URINE VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DISEASE MODELS, ANIMAL; DNA DAMAGE; EPITHELIAL CELLS; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; NEPHRITIS; RISK FACTORS;

EID: 79952142018     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2112490     Document Type: Review

References (225)

1. Hartmann, J.T.; Fels, L.M.; Knop, S.; Stolt, H.; Kanz, L.; Bokemeyer, C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest. New Drugs 2000, 18, 281-289.
2. Hartmann, J.T.; Lipp, H.-P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4, 889-901.
3. Sastry, J.; Kellie, S.J. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr. Hematol. Oncol. 2005, 22, 441-445.
4. Arany, I.; Safirstein, R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23, 460-464.
5. Boulikas, T. Poly(ADP-ribose) synthesis in blocked and damaged cells and its relation to carcinogens. Anticancer Res. 1992, 12, 885-898.
6. Planting, A.; Catimel, G.; de Mulder, P.; de Graeff, A.; Hoppener, F.; Verweij, J.; Oster, W.; Vermorken, J. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann. Oncol. 1999, 10, 693-700.
7. Loehrer, P.J.; Gonin, R.; Nichols, C.R.; Weathers, T.; Einhorn, L.H. Vinblastine plus ifosphamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J. Clin. Oncol. 1998, 16, 2500-2504.
8. Noda, K.; Nishiwaki, Y.; Kawahara, M.; Negoro, S.; Sugiura, T.; Yokoyama, A.; Saijo, N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002, 346, 85-91.
9. Gatzemeier, U.; von Pawel, J.; ten Velde, G.; Mattson, K.; DeMarinis, F.; Harper, P.; Salvati, F.; Robinet, G.; Lucenti, A.; Bogarerts, J.; Gallant, G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small- cell lung cancer. J. Clin. Oncol. 2000, 18, 3390-3399.
10. Bolis, G.; Favalli, G.; Danese, S.; Zanaboni, F.; Mangili, G.; Scarabelli, C.; Tateo, S.; Valsecchi, M.; Scarfone, G.; Richiardi, G.; Frigerio, L.; Melpignano, M.; Villa, A.; Parazzini, F. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J. Clin. Oncol. 1997, 15, 1938-1944.
11. Hoskins, P.; Eisenhauer, E.; Vergote, I.; Dubuc-Lissoir, J.; Fisher, B.; Grimshaw, R.; Oza, A.; Plante, M.; Stuart, G.; Vermorken, J. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paciltaxel/cisplatin as primary treatment of advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 2000, 18, 4038-4044.
12. Rose, P.; Bundy, B.; Watkins, E.; Thigpen, J.; Deppe, G.; Maiman, M.; Clarke-Pearson, D.; Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999, 340, 1144-1153.
13. Coppin, C.; Gospodarowicz, M.; James, K.; Tannock, I.; Zee, B.; Carson, J.; Peter, J.; Sullivan, D. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J. Clin. Oncol. 1996, 14, 2901-2907.
14. Pritchard, J.; Brown, J.; Shafford, E.; Perilongo, G.; Brock, P.; Dicks-Mireaux, C.; Keeling, J.; Phillips, A.; Vos, A.; Plaschkes, J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach-results of the first prospective study of the Internal Society of Pediatric Oncology. J. Clin. Oncol. 2000, 18, 3819-3828.
15. Madias, N.E.; Harrington, J.T. Platinum nephrotoxicity. Am. J. Med. 1978, 65, 307-314.
16. Goldstein, R.S.; Mayor, G.H. Minireview. The nephrotoxicity of cisplatin. Life Sci. 1983, 32, 685-690.
17. Schilsky, R.L.; Anderson, T.O.M. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann. Intern. Med. 1979, 90, 929-931.
18. Lam, M.; Adelstein, D.J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am. J. Kidney Dis. 1986, 8, 164-169.
19. Ries, F.; Klastersky, J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis. 1986, 13, 368-379.
20. Sutton, R.A.; Walker, V.R.; Halabe, A.; Swenerton, K.; Coppin, C.M. Chronic hypomagnesemia caused by cisplatin: Effect of calcitriol. J. Lab. Clin. Med. 1991, 117, 40-43.
21. Parfitt, A.; Kleerekoper, M. Clinical disorders of calcium, phosphorous and magnesium metabolism. In Clinical Disorders of Fluid and Electrolyte Metabolism; Maxwell, M., Kleeman, C., Eds.; McGraw-Hill: New York, NY, USA, 1980.
22. Kim, Y.K.; Byun, H.S.; Kim, Y.H.; Woo, J.S.; Lee, S.H. Effect of Cisplatin on renal-function in rabbits: Mechanism of reduced glucose reabsorption. Toxicol. Appl. Pharmacol. 1995, 130, 19-26.
23. Wangila, G.W.; Nagothu, K.K.; Steward, R., III; Bhatt, R.; Iyere, P.A.; Willingham, W.M.; Sorenson, J.R.; Shah, S.V.; Portilla, D. Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper2II(3,5-ditertiarybutylsalicylate)4(ethanol)4]. Toxicol. In Vitro 2006, 20, 1300-1312.
24. Goldstein, R.S.; Mayor, G.H.; Rosenbaum, R.W.; Hook, J.B.; Santiago, J.V.; Bond, J.T. Glucose intolerance following cis-platinum treatment in rats. Toxicology 1982, 24, 273-280.
25. Goldstein, R.S.; Mayor, G.H.; Gingerich, R.L.; Hook, J.B.; Rosenbaum, R.W.; Bond, J.T. The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol. Appl. Pharmacol. 1983, 69, 432-441.
26. Oeffinger, K.; Hudson, M. Long-term complications following childhood and adolescent cancer: Foundations for providing risk-based health care for survivors. CA Cancer J. Clin. 2004, 54, 208-236.
27. Swainson, C.P.; Colls, B.M.; Fitzharris, B.M. Cis-platinum and distal renal tubule toxicity. N. Z. Med. J. 1985, 98, 375-378.
28. Suh, S.M.; Tashjian, A.H.; Matsuo, N.; Parkinson, D.K.; Fraser, D. Pathogenesis of hypocalcemia in primary hypomagnesemia: Normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function. J. Clin. Invest. 1973, 52, 153-160.
29. Connor, T.B.; Toskes, P.; Mahaffey, J.; Martin, L.G.; Williams, J.B.; Walser, M. Parathyroid function during chronic magnesium deficiency. Johns Hopkins Med. J. 1972, 131, 100-117.
30. Hutchison, F.N.; Perez, E.A.; Gandara, D.R.; Lawrence, H.J.; Kaysen, G.A. Renal salt wasting in patients treated with cisplatin. Ann. Intern. Med. 1988, 108, 21-25.
31. Cao, L.M.D.; Joshi, P.M.D.; Sumoza, D.M.D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: Case report. Am. J. Clin. Oncol. 2002, 25, 344-346.
32. Kurtzberg, J.; Dennis, V.W.; Kinney, T.R. Cisplatinum-induced renal salt wasting. Med. Pediatr. Oncol. 1984, 12, 150-154.
33. Shakhov, A.; Collart, M.; Vassalli, P.; Nedospasov, S.; Jongeneel, C. kB-Type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J. Exp. Med. 1990, 171, 35-47.
34. Seguro, A.C.; Shimizu, M.H.; Kudo, L.H.; dos Santos Rocha, A. Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am. J. Nephrol. 1989, 9, 59-65.
35. Lammers, P.J.; White, L.; Ettinger, L.J. Cis-platinum-induced renal sodium wasting. Med. Pediatr. Oncol. 1984, 12, 343-346.
36. Tscherning, C.; Hervé, R.; Chancholle, A.; Claeyssens, S.; Robert, A.; Fabre, J.; Bouissou, F. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994, 73, 1761-1763.
37. Safirstein, R.; Miller, P.; Dikman, S.; Lyman, N.; Shapiro, C. Cisplatin nephrotoxicity in rats: Defect in papillary hypertonicity. Am. J. Physiol. Renal Physiol. 1981, 241, F175-F185.
38. Gordon, J.A.; Peterson, L.N.; Anderson, R.J. Water metabolism after cisplatin in the rat. Am. J. Physiol. Renal Physiol. 1982, 243, F36-F43.
39. Safirstein, R.; Zelent, A.; Gordon, R. Cisplatin nephrotoxicity: New insights into mechanism. In Organ Directed Toxicities of Anticancer Drugs, Proceedings of the First International Symposium on the Organ Directed Toxicities of Anticancer Drugs, Burlington, VT, USA, June 4-6, 1987; Hacker, M.P., Lazo, J.S., Tritton, T.R., Eds.; Martinus Nijhoff Publishers: Boston, MA, USA, 1988; p. 174.
40. Launay-Vacher, V.; Rey, J.B.; Isnard-Bagnis, C.; Deray, G.; Daouphars, M. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother. Pharmacol. 2008, 61, 903-909.
41. Nanji, A.A.; Mikhael, N.Z.; Stewart, D.J. Increase in serum uric acid level associated with cisplatin therapy: Correlation with liver but not kidney platinum concentrations. Arch. Intern. Med. 1985, 145, 2013-2014.
42. DeConti, R.C.; Toftness, B.R.; Lange, R.C.; Creasey, W.A. Clinical and pharmacological studies with cis-Diamminedichloroplatinum(II). Cancer Res. 1973, 33, 1310-1315.
43. Wood, P.A.; Hrushesky, W.J. Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J. Clin. Invest. 1995, 95, 1650-1659.
44. Jackson, A.M.; Rose, B.D.; Graff, L.G.; Jacobs, J.B.; Schwartz, J.H.; Strauss, G.M.; Yang, J.P.S.; Rudnick, M.R.; Elfenbein, I.B.; Narins, R.G. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann. Intern. Med. 1984, 101, 41-44.
45. Brillet, G.; Deray, G.; Jacquiaud, C.; Mignot, L.; Bunker, D.; Meillet, D.; Raymond, F.; Jacobs, C. Long-term renal effect of cisplatin in man. Am. J. Nephrol. 1994, 14, 81-84.
46. Koch Nogueira, P.C.; Hadj-Aïssa, A.; Schell, M.; Dubourg, L.; Brunat-Mentigny, M.; Cochat, P. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr. Nephrol. 1998, 12, 572-575.
47. Rosenberg, B.; Vancamp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205, 698-699.
48. Rosenberg, B.; VanCamp, L.; Trosko, J.E.; Mansour, V.H. Platinum compounds: A new class of potent antitumour agents. Nature 1969, 222, 385-386.
49. Kociba, R.J.; Sleight, S.D. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother. Rep. 1971, 55, 1-8.
50. Hartmann, J.T.; Kollmannsberger, C.; Kanz, L.; Bokemeyer, C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer 1999, 83, 866-869.
51. Santoso, J.T.; Lucci, J.A., III; Coleman, R.L.; Schafer, I.; Hannigan, E.V. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother. Pharmacol. 2003, 52, 13-18.
52. Taguchi, T.; Nazneen, A.; Abid, M.R.; Razzaque, M.S. Cisplatin-associated nephrotoxicity and pathological events. Contrib. Nephrol. 2005, 148, 107-121.
53. Reece, P.A.; Stafford, I.; Russell, J.; Khan, M.; Gill, P.G. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J. Clin. Oncol. 1987, 5, 304-309.
54. de Jongh, F.E.; Verweij, J.; Loos, W.J.; de Wit, R.; de Jonge, M.J.A.; Planting, A.S.T.; Nooter, K.; Stoter, G.; Sparreboom, A. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol. 2001, 19, 3733-3739.
55. de Jongh, F.E.; van Veen, R.N.; Veltman, S.J.; de Wit, R.; van der Burg, M.E.L.; van den Bent, M.J.; Planting, A.; Graveland, W.J.; Stoter, G.; Verweij, J. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 2003, 88, 1199-1206.
56. Raj, G.V.; Iasonos, A.; Herr, H.; Donat, S.M. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J. Clin. Oncol. 2006, 24, 3095-3100.
57. Scott, L.A.; Madan, E.; Valentovic, M.A. Attenuation of cisplatin nephrotoxicity by streptozotocin-induced diabetes. Fundam. Appl. Toxicol. 1989, 12, 530-539.
58. Gogas, H.; Shapiro, F.; Aghajanian, C.; Fennelly, D.; Almadrones, L.; Hoskins, W.J.; Spriggs, D.R. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol. Oncol. 1996, 61, 22-26.
59. Stewart, D.J.; Dulberg, C.S.; Mikhael, N.Z.; Redmond, M.D.; Montpetit, V.A.; Goel, R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother. Pharmacol. 1997, 40, 293-308.
60. Filipski, K.K.; Mathijssen, R.H.; Mikkelsen, T.S.; Schinkel, A.H.; Sparreboom, A. contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 2009, 86, 396-402.
61. Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstadt, H.; Lanvers-Kaminsky, C.; am Zehnhoff-Dinnesen, A.; Schinkel, A.H.; Koepsell, H.; Jurgens, H.; Schlatter, E. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176, 1169-1180.
62. Yao, X.; Panichpisal, K.; Kurtzman, N.; Nugent, K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci. 2007, 334, 115-124.
63. Safirstein, R.; Miller, P.; Guttenplan, J.B. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984, 25, 753-758.
64. Endo, T.; Kimura, O.; Sakata, M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology 2000, 146, 187-195.
65. Kolb, R.; Ghazi, M.; Barfuss, D. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-L-cysteine-cDDP by TEA and PAH in the renal proximal tubule. Cancer Chemother. Pharmacol. 2003, 51, 132-138.
66. Ishida, S.; Lee, J.; Thiele, D.J.; Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA 2002, 99, 14298-14302.
67. Holzer, A.K.; Samimi, G.; Katano, K.; Naerdemann, W.; Lin, X.; Safaei, R.; Howell, S.B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2004, 66, 817-823.
68. Pabla, N.; Murphy, R.F.; Liu, K.; Dong, Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009, 296, F505-F511.
69. Ludwig, T.; Riethmuller, C.; Gekle, M.; Schwerdt, G.; Oberleithner, H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004, 66, 196-202.
70. Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstadt, H.; Koepsell, H.; Piechota, H.J.; Haier, J.; Jaehde, U.; Zisowsky, J.; Schlatter, E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167, 1477-1484.
71. Filipski, K.K.; Loos, W.J.; Verweij, J.; Sparreboom, A. Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 2008, 14, 3875-3880.
72. Yonezawa, A.; Masuda, S.; Yokoo, S.; Katsura, T.; Inui, K.-I. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 2006, 319, 879-886.
73. Townsend, D.M.; Tew, K.D.; He, L.; King, J.B.; Hanigan, M.H. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed. Pharmacother. 2009, 63, 79-85.
74. Sadzuka, Y.; Shimizu, Y.; Takino, Y.; Hirota, S. Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. Biochem. Pharmacol. 1994, 48, 453-459.
75. Townsend, D.M.; Deng, M.; Zhang, L.; Lapus, M.G.; Hanigan, M.H. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J. Am. Soc. Nephrol. 2003, 14, 1-10.
76. Townsend, D.M.; Hanigan, M.H. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J. Pharmacol. Exp. Ther. 2002, 300, 142-148.
77. Zhang, L.; Hanigan, M.H. Role of cysteine S-conjugate β-lyase in the metabolism of cisplatin. J. Pharmacol. Exp. Ther. 2003, 306, 988-994.
78. Pascoe, J.M.; Roberts, J.J. Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds. Biochem. Pharmacol. 1974, 23, 1359-1365.
79. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307-320.
80. Burger, H.; Nooter, K.; Boersma, A.W.M.; Kortland, C.J.; Stoter, G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int. J. Cancer 1997, 73, 592-599.
81. Mandic, A.; Hansson, J.; Linder, S.; Shoshan, M.C. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J. Biol. Chem. 2003, 278, 9100-9106.
82. Cullen, K.J.; Yang, Z.; Schumaker, L.; Guo, Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr. 2007, 39, 43-50.
83. Qian, W.; Nishikawa, M.; Haque, A.M.; Hirose, M.; Mashimo, M.; Sato, E.; Inoue, M. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am. J. Physiol. Cell Physiol. 2005, 289, C1466-C1475.
84. Hirama, M.; Isonishi, S.; Yasuda, M.; Ishikawa, H. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol. Rep. 2006, 16, 997-1002.
85. Gullans, S.R.; Mandel, L.J. Coupling of energy transport in proximal and distal nephron. In The Kidney: Physiology and Pathophysiology, 3rd ed.; Seldin, D.W., Giebisch, G., Eds.; Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2000; Volume 1, pp. 445-482.
86. Olivero, O.A.; Chang, P.K.; LopezLarraza, D.M.; SeminoMora, M.C.; Poirier, M.C. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 1997, 391, 79-86.
87. Li, S.; Wu, P.; Yarlagadda, P.; Vadjunec, N.M.; Proia, A.D.; Harris, R.A.; Portilla, D. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am. J. Physiol. Renal Physiol. 2004, 286, F572-F580.
88. Portilla, D.; Dai, G.; McClure, T.; Bates, L.; Kurten, R.; Megyesi, J.; Price, P.; Li, S. Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int. 2002, 62, 1208-1218.
89. Li, S.; Basnakian, A.; Bhatt, R.; Megyesi, J.; Gokden, N.; Shah, S.V.; Portilla, D. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am. J. Physiol. Renal Physiol. 2004, 287, F990-F998.
90. Kruidering, M.; Van de Water, B.; de Heer, E.; Mulder, G.J.; Nagelkerke, J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: Mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 1997, 280, 638-649.
91. Arany, I.; Kaushal, G.P.; Portilla, D.; Megyesi, J.; Price, P.M.; Safirstein, R.L. Cellular mechanisms of nephrotoxicity. In Clinical Nephrotoxins; Broe, M.E.D., Porter, G.A., Bennett, W.M., Deray, G., Eds.; Springer: New York, NY, USA, 2008; pp. 155-170.
92. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008, 73, 994-1007.
93. Jiang, M.; Dong, Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J. Pharmacol. Exp. Ther. 2008, 327, 300-307.
94. Lieberthal, W.; Triaca, V.; Levine, J. Mechanisms of death induced by cisplatin in proximal tubular eipthelial cells: Apoptosis vs. necrosis. Am. J. Physiol. Renal Physiol. 1996, 270, F700-F708.
95. Lee, R.H.; Song, J.M.; Park, M.Y.; Kang, S.K.; Kim, Y.K.; Jung, J.S. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem. Pharmacol. 2001, 62, 1013-1023.
96. Shiraishi, F.; Curtis, L.; Truong, L.; Poss, K.; Visner, G.; Madsen, K.; Nick, H.; Agarwal, A. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am. J. Physiol. Renal Physiol. 2000, 278, F726-F736.
97. Megyesi, J.; Safirstein, R.L.; Price, P.M. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J. Clin. Invest. 1998, 101, 777-782.
98. Ramesh, G.; Reeves, W.B. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney Int. 2004, 65, 490-498.
99. Tsuruya, K.; Ninomiya, T.; Tokumoto, M.; Hirakawa, M.; Matsutani, K.; Taniguchi, M.; Fukuda, K.; Kanai, H.; Kishihara, K.; Hirakata, H.; Iida, M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int. 2003, 63, 72-82.
100. Seth, R.; Yang, C.; Kaushal, V.; Shah, S.V.; Kaushal, G.P. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J. Biol. Chem. 2005, 280, 31230-31239.
101. Takeda, M.; Kobayashi, M.; Shirato, I.; Osaki, T.; Endou, H. Cisplatin-induced apoptosis of immortalized mouse proximal tubule cells is mediated by interleukin-1 beta converting enzyme (ICE) family of proteases but inhibited by overexpression of Bcl-2. Arch. Toxicol. 1997, 71, 612-621.
102. Ramesh, G.; Reeves, W.B. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002, 110, 835-842.
103. Ramesh, G.; Reeves, W.B. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am. J. Physiol. Renal Physiol. 2003, 285, F610-F618.
104. Cilenti, L.; Kyriazis, G.A.; Soundarapandian, M.M.; Stratico, V.; Yerkes, A.; Park, K.M.; Sheridan, A.M.; Alnemri, E.S.; Bonventre, J.V.; Zervos, A.S. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am. J. Physiol. Renal Physiol. 2005, 288, F371-F379.
105. Park, M.S.; De Leon, M.; Devarajan, P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J. Am. Soc. Nephrol. 2002, 13, 858-865.
106. Nagothu, K.K.; Bhatt, R.; Kaushal, G.P.; Portilla, D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int. 2005, 68, 2680-2693.
107. Jiang, M.; Wei, Q.; Wang, J.; Du, Q.; Yu, J.; Zhang, L.; Dong, Z. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006, 25, 4056-4066.
108. Wei, Q.; Dong, G.; Franklin, J.; Dong, Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int. 2007, 72, 53-62.
109. Jiang, M.; Wang, C.-Y.; Huang, S.; Yang, T.; Dong, Z. Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am. J. Physiol. Renal Physiol. 2009, 296, F983-F993.
110. Yin, X.; Apostolov, E.O.; Shah, S.V.; Wang, X.; Bogdanov, K.V.; Buzder, T.; Stewart, A.G.; Basnakian, A.G. Induction of renal endonuclease G by cisplatin is reduced in DNase I-deficient mice. J. Am. Soc. Nephrol. 2007, 18, 2544-2553.
111. Dursun, B.; He, Z.; Somerset, H.; Oh, D.J.; Faubel, S.; Edelstein, C.L. Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am. J. Physiol. Renal Physiol. 2006, 291, F578-F587.
112. Fukuoka, K.; Takeda, M.; Kobayashi, M.; Osaki, T.; Shirato, I.; Soejima, A.; Nagasawa, T.; Endou, H. Distinct interleukin-1beta-converting enzyme family proteases mediate cisplatin- and staurosporine-induced apoptosis of mouse proximal tubule cells. Life Sci. 1998, 62, 1125-1138.
113. Kaushal, G.; Kaushal, V.; Hong, X.; Shah, S. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 2001, 60, 1726-1736.
114. Yang, C.; Kaushal, V.; Haun, R.S.; Seth, R.; Shah, S.V.; Kaushal, G.P. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ. 2008, 15, 530-544.
115. Jiang, M.; Yi, X.; Hsu, S.; Wang, C.Y.; Dong, Z. Role of p53 in cisplatin-induced tubular cell apoptosis: Dependence on p53 transcriptional activity. Am. J. Physiol. Renal Physiol. 2004, 287, F1140-F1147.
116. Liu, H.; Baliga, R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J. Am. Soc. Nephrol. 2005, 16, 1985-1992.
117. 2+-independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J. Pharmacol. Exp. Ther. 2004, 308, 921-928.
118. Peyrou, M.; Hanna, P.E.; Cribb, A.E. Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol. Sci. 2007, 99, 346-353.
119. Kaushal, G.P.; Kaushal, V.; Herzog, C.; Yang, C. Autophagy delays apoptosis in renal tubular epithelial cells in cisplatin cytotoxicity. Autophagy 2008, 4, 710-712.
120. Yang, C.; Kaushal, V.; Shah, S.V.; Kaushal, G.P. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2008, 294, F777-F787.
121. Periyasamy-Thandavan, S.; Jiang, M.; Wei, Q.; Smith, R.; Yin, X.M.; Dong, Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 2008, 74, 631-640.
122. WAF1/CIP1/SDI1 after acute renal failure. Am. J. Physiol. Renal Physiol. 1996, 271, F1211-F1216.
123. Price, P.M.; Safirstein, R.L.; Megyesi, J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am. J. Physiol. Renal Physiol. 2004, 286, F378-F384.
124. Price, P.M.; Yu, F.; Kaldis, P.; Aleem, E.; Nowak, G.; Safirstein, R.L.; Megyesi, J. Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J. Am. Soc. Nephrol. 2006, 17, 2434-2442.
125. Yu, F.; Megyesi, J.; Safirstein, R.L.; Price, P.M. Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am. J. Physiol. Renal Physiol. 2005, 289, F514-F520.
126. Bassett, E.A.; Wang, W.; Rastinejad, F.; El-Deiry, W.S. Structural and functional basis for therapeutic modulation of p53 signaling. Clin. Cancer Res. 2008, 14, 6376-6386.
127. Wei, Q.; Dong, G.; Yang, T.; Megyesi, J.; Price, P.M.; Dong, Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am. J. Physiol. Renal Physiol. 2007, 293, F1282-F1291.
128. Cummings, B.S.; Schnellmann, R.G. Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2002, 302, 8-17.
129. Molitoris, B.A.; Dagher, P.C.; Sandoval, R.M.; Campos, S.B.; Ashush, H.; Fridman, E.; Brafman, A.; Faerman, A.; Atkinson, S.J.; Thompson, J.D.; Kalinski, H.; Skaliter, R.; Erlich, S.; Feinstein, E. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J. Am. Soc. Nephrol. 2009, 20, 1754-1764.
130. Lebedeva, M.A.; Eaton, J.S.; Shadel, G.S. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim. Biophys. Acta Bioenerg. 2009, 1787, 328-334.
131. Yoshida, Y.; Izumi, H.; Torigoe, T.; Ishiguchi, H.; Itoh, H.; Kang, D.; Kohno, K. p53 physically interacts with mitochondrial transcription factor a and differentially regulates binding to damaged DNA. Cancer Res. 2003, 63, 3729-3734.
132. Jiang, M.; Wei, Q.; Pabla, N.; Dong, G.; Wang, C.Y.; Yang, T.; Smith, S.B.; Dong, Z. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem. Pharmacol. 2007, 73, 1499-1510.
133. Pabla, N.; Huang, S.; Mi, Q.-S.; Daniel, R.; Dong, Z. ATR-Chk2 Signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J. Biol. Chem. 2008, 283, 6572-6583.
134. Basnakian, A.G.; Apostolov, E.O.; Yin, X.; Napirei, M.; Mannherz, H.G.; Shah, S.V. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J. Am. Soc. Nephrol. 2005, 16, 697-702.
135. Yin, X.; Apostolov, E.O.; Shah, S.V.; Wang, X.; Bogdanov, K.V.; Buzder, T.; Stewart, A.G.; Basnakian, A.G. Induction of renal endonuclease G by cisplatin is reduced in DNase I-deficient mice. J. Am. Soc. Nephrol. 2007, 18, 2544-2553.
136. Dong, G.; Wang, L.; Wang, C.-Y.; Yang, T.; Kumar, M.V.; Dong, Z. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. J. Pharmacol. Exp. Ther. 2008, 325, 978-984.
137. Dong, G.; Luo, J.; Kumar, V.; Dong, Z. Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am. J. Physiol. Renal Physiol. 2010, 298, F293-F300.
138. Arany, I.; Herbert, J.; Herbert, Z.; Safirstein, R.L. Restoration of CREB function ameliorates cisplatin cytotoxicity in renal tubular cells. Am. J. Physiol. Renal Physiol. 2008, 294, F577-F581.
139. Li, H.-F.; Cheng, C.-F.; Liao, W.-J.; Lin, H.; Yang, R.-B. ATF3-mediated epigenetic regulation protects against acute kidney injury. J. Am. Soc. Nephrol. 2010, 21, 1003-1013.
140. Jo, S.K.; Cho, W.Y.; Sung, S.A.; Kim, H.K.; Won, N.H. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 2005, 67, 458-466.
141. Francescato, H.D.; Costa, R.S.; Junior, F.B.; Coimbra, T.M. Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol. Dial. Transplant. 2007, 22, 2138-2148.
142. Ramesh, G.; Reeves, W.B. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am. J. Physiol. Renal Physiol. 2005, 289, F166-F174.
143. Kim, Y.K.; Kim, H.J.; Kwon, C.H.; Kim, J.H.; Woo, J.S.; Jung, J.S.; Kim, J.M. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J. Appl. Toxicol. 2005, 25, 374-382.
144. Clark, J.S.; Faisal, A.; Baliga, R.; Nagamine, Y.; Arany, I. Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells. Cancer Lett. 2010, 297, 165-170.
145. Baliga, R.; Zhang, Z.; Baliga, M.; Ueda, N.; Shah, S.V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998, 53, 394-401.
146. Davis, C.; Nick, H.; Agarwal, A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: Importance of superoxide. J. Am. Soc. Nephrol. 2001, 12, 2683-2690.
147. Appendroth, D.; Frob, S.; Kersten, L.; Splinter, F.K.; Winnefeld, K. Protective effects of Vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch. Toxicol. 1997, 71, 677-683.
148. Dickey, D.T.; Wu, Y.J.; Muldoon, L.L.; Neuwelt, E.A. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J. Pharmacol. Exp. Ther. 2005, 314, 1052-1058.
149. Ma, S.F.; Nishikawa, M.; Hyoudou, K.; Takahashi, R.; Ikemura, M.; Kobayashi, Y.; Yamashita, F.; Hashida, M. Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity. Kidney Int. 2007, 72, 1474-1482.
150. Naziroglu, M.; Karaoglu, A.; Aksoy, A.O. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004, 195, 221-230.
151. Kelly, K.J.; Meehan, S.M.; Colvin, R.B.; Williams, W.W.; Bonventre, J.V. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 1999, 56, 922-931.
152. Deng, J.; Kohda, Y.; Chiao, H.; Wang, Y.; Hu, X.; Hewitt, S.; Miyaja, T.; McLeroy, P.; Nibhanupudy, B.; Li, S.; Star, R. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001, 60, 2118-2128.
153. Kim, Y.; Choi, T.; Kwon, C.; Kim, J.; Woo, J.; Jung, J. Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Ren. Fail. 2003, 25, 909-922.
154. Zhang, B.; Ramesh, G.; Norbury, C.; Reeves, W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells. Kidney Int. 2007, 72, 37-44.
155. Barbara, J.A.J.; Smith, W.; Gamble, J.; Ostade, X.; Vandenabelle, P.; Tavernier, J.; Fiers, W.; Vadas, M.; Lopez, A. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-α mutants. EMBO J. 1994, 14, 843-850.
156. Locksley, R.; Killeen, N.; Lenardo, M. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001, 104, 487-501.
157. Faubel, S.; Lewis, E.C.; Reznikov, L.; Ljubanovic, D.; Hoke, T.S.; Somerset, H.; Oh, D.-J.; Lu, L.; Klein, C.L.; Dinarello, C.A.; Edelstein, C.L. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 2007, 322, 8-15.
158. Lu, L.H.; Oh, D.J.; Dursun, B.; He, Z.; Hoke, T.S.; Faubel, S.; Edelstein, C.L. Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J. Pharmacol. Exp. Ther. 2008, 324, 111-117.
159. Faubel, S.; Ljubanovic, D.; Reznikov, L.; Somerset, H.; Dinarello, C.A.; Edelstein, C.L. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int. 2004, 66, 2202-2213.
160. Tadagavadi, R.K.; Reeves, W.B. Endogenous IL-10 attenuates cisplatin nephrotoxicity: Role of dendritic cells. J. Immunol. 2010, 185, 4904-4911.
161. de Waal Malefyt, R. IL-10. In Cytokine Reference; Oppenheim, J.J., Feldmann, M., Eds.; Academic Press: San Diego, CA, USA, 2001; Volume 1, pp. 165-185.
162. Zhang, B.; Ramesh, G.; Uematsu, S.; Akira, S.; Reeves, W.B. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J. Am. Soc. Nephrol. 2008, 19, 923-932.
163. Zhang, B.; Ramesh, G.; Wang, W.; Kwon, O.; Ahn, K.; Freeman, W.; Reeves, W.B. Urinary Cytokine Profiles in Different Forms of Acute Kidney Injury. 2010, manuscript in preparation.
164. McDuffie, J.E.; Sablad, M.; Ma, J.; Snook, S. Urinary parameters predictive of cisplatin-induced acute renal injury in dogs. Cytokine 2010, doi:10.1016/j.cyto.2010.06.005.
165. Gluba, A.; Banach, M.; Hannam, S.; Mikhailidis, D.P.; Sakowicz, A.; Rysz, J. The role of Toll-like receptors in renal diseases. Nat. Rev. Nephrol. 2010, 6, 224-235.
166. Kono, H.; Rock, K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008, 8, 279-289.
167. Cunningham, P.N.; Dyanov, H.M.; Park, P.; Wang, J.; Newell, K.A.; Quigg, R.J. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J. Immunol. 2002, 168, 5817-5823.
168. Cunningham, P.N.; Wang, Y.; Guo, R.; He, G.; Quigg, R.J. Role of toll-like receptor 4 in endotoxin-induced acute renal failure. J. Immunol. 2004, 172, 2629-2635.
169. Zager, R.A.; Johnson, A.C.M.; Hanson, S.Y.; Lund, S. Acute nephrotoxic and obstructive injury primes the kidney to endotoxin-driven cytokine/chemokine production. Kidney Int. 2006, 69, 1181-1188.
170. Ramesh, G.; Kimball, S.R.; Jefferson, L.S.; Reeves, W.B. Endotoxin and cisplatin synergistically stimulate TNF-{alpha} production by renal epithelial cells. Am. J. Physiol. Renal Physiol. 2007, 292, F812-F819.
171. Ramesh, G.; Zhang, B.; Uematsu, S.; Akira, S.; Reeves, W.B. Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am. J. Physiol. Renal Physiol. 2007, 293, F325-F332.
172. Tsung, A.; Klune, J.R.; Zhang, X.; Jeyabalan, G.; Cao, Z.; Peng, X.; Stolz, D.B.; Geller, D.A.; Rosengart, M.R.; Billiar, T.R. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 2007, 204, 2913-2923.
173. Pan, P.; Cardinal, J.; Dhupar, R.; Rosengart, M.R.; Lotze, M.T.; Geller, D.A.; Billiar, T.R.; Tsung, A. Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J. Leukoc. Biol. 2009, 86, 625-632.
174. Leemans, J.C.; Stokman, G.; Claessen, N.; Rouschop, K.M.; Teske, G.J.D.; Kirschning, C.J.; Akira, S.; van der Poll, T.; Weening, J.J.; Florquin, S. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 2005, 115, 2894-2903.
175. Zubin, M.B.; Vinod, P.B.; Lee, M.O.; Hebroon, O.; George, P.; Ronald, P.D. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 2010, 51, 621-632.
176. Yi, A.-K.; Yoon, H.; Park, J.-E.; Kim, B.-S.; Kim, H.J.; Martinez-Hernandez, A. CpG DNA- mediated induction of acute liver injury in d-Galactosamine-sensitized mice: The mitochondrial apoptotic pathway-dependent death of hepatocytes. J. Biol. Chem. 2006, 281, 15001-15012.
177. Yasuda, H.; Leelahavanichkul, A.; Tsunoda, S.; Dear, J.W.; Takahashi, Y.; Ito, S.; Hu, X.; Zhou, H.; Doi, K.; Childs, R.; Klinman, D.M.; Yuen, P.S.; Star, R.A. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am. J. Physiol. Renal Physiol. 2008, 294, F1050-F1058.
178. Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464, 104-107.
179. Tadagavadi, R.K.; Reeves, W.B. TLR9 in cisplatin nephrotoxicity. College of Medicine, Pennsylvania State University, Hershey, PA, USA, 2010, unpublished work.
180. Tadagavadi, R.K.; Reeves, W.B., Renal dendritic cells ameliorate nephrotoxic acute kidney injury. J. Am. Soc. Nephrol. 2010, 21, 53-63.
181. Oh, D.-J.; Dursun, B.; He, Z.; Lu, L.; Hoke, T.S.; Ljubanovic, D.; Faubel, S.; Edelstein, C.L. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am. J. Physiol. Renal Physiol. 2008, 294, F264-F271.
182. Li, L.; Huang, L.; Sung, S.S.; Vergis, A.L.; Rosin, D.L.; Rose, C.E., Jr.; Lobo, P.I.; Okusa, M.D. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int. 2008, 74, 1526-1537.
183. Tarang, S.; Sodhi, A.; Chauhan, P. Differential expression of Toll-like receptors in murine peritoneal macrophages in vitro on treatment with cisplatin. Int. Immunol. 2007, 19, 635-643.
184. Chauhan, P.; Sodhi, A.; Shrivastava, A. Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929 cells. Immunobiology 2009, 214, 197-209.
185. + T Cells as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest. 2001, 108, 1283-1290.
186. Liu, M.; Chien, C.-C.; Burne-Taney, M.; Molls, R.R.; Racusen, L.C.; Colvin, R.B.; Rabb, H. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 2006, 17, 765-774.
187. Lee, V.W.; Wang, Y.M.; Wang, Y.P.; Zheng, D.; Polhill, T.; Cao, Q.; Wu, H.; Alexander, I.E.; Alexander, S.I.; Harris, D.C. Regulatory immune cells in kidney disease. Am. J. Physiol. Renal Physiol. 2008, 295, F335-F342.
188. + regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int. 2009, 76, 717-729.
189. Kinsey, G.R.; Sharma, R.; Huang, L.; Li, L.; Vergis, A.L.; Ye, H.; Ju, S.-T.; Okusa, M.D. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2009, 20, 1744-1753.
190. Lee, H.; Nho, D.; Chung, H.S.; Lee, H.; Shin, M.K.; Kim, S.H.; Bae, H. CD4(+)CD25(+) regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. Kidney Int. 2010, doi:10.1038/ki.2010.139.
191. Laouar, Y.; Town, T.; Jeng, D.; Tran, E.; Wan, Y.; Kuchroo, V.K.; Flavell, R.A. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2008, 105, 10865-10870.
192. Akbari, O.; DeKruyff, R.H.; Umetsu, D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2001, 2, 725-731.
193. Akbari, O.; Freeman, G.J.; Meyer, E.H.; Greenfield, E.A.; Chang, T.T.; Sharpe, A.H.; Berry, G.; DeKruyff, R.H.; Umetsu, D.T. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 2002, 8, 1024-1032.
194. + T cells by exogenous cell-associated antigens. Immunity 2002, 17, 211-220.
195. + dendritic cells during allergen challenge abrogates the characteristic features of asthma. J. Exp. Med. 2005, 201, 981-991.
196. + interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 2006, 70, 591-596.
197. Dong, X.; Swaminathan, S.; Bachman, L.A.; Croatt, A.J.; Nath, K.A.; Griffin, M.D. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int. 2007, 71, 619-628.
198. Cornelison, T.L.; Reed, E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol. Oncol. 1993, 50, 147-158.
199. Lehane, D.; Winston, A.; Gray, R.; Daskal, Y. The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5, 1393-1399.
200. Al-Sarraf, M.; Fletcher, W.; Oishi, N.; Pugh, R.; Hewlett, J.S.; Balducci, L.; McCracken, J.; Padilla, F. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A southwest oncology group study. Cancer Treat. Rep. 1982, 66, 31-35.
201. Levi, J.; Jacobs, C.; Kalman, S.M.; McTigue, M.; Weiner, M.W. Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. J. Pharmacol. Exp. Ther. 1980, 213, 545-550.
202. Safirstein, R.; Winston, J.; Moel, D.; Dikman, S.; Guttenplan, J. Cisplatin nephrotoxicity: Insights into mechanism. Int. J. Androl. 1987, 10, 325-346.
203. Hensley, M.L.; Hagerty, K.L.; Kewalramani, T.; Green, D.M.; Meropol, N.J.; Wasserman, T.H.; Cohen, G.I.; Emami, B.; Gradishar, W.J.; Mitchell, R.B.; et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 2009, 27, 127-145.
204. Castiglione, F.; Mola, A.D.; Porcile, G. Protection of normal tissues from radiation and cytotoxic therapy: The development of amifostine. Tumori 1999, 85, 85-91.
205. Capizzi, R.L. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: Laboratory and clinical aspects. Semin. Oncol. 1999, 26, 72-81.
206. Yasuo, M.; Yasuhiro, M.; Tetsuya, H.; Nobuhiro, N.; Kazunori, K.; Takanori, K.; William, J.M.H.; Fuminori, M.; Tadao, K. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Cancer Sci. 2001, 92, 328-336.
207. Uchino, H.; Matsumura, Y.; Negishi, T.; Koizumi, F.; Hayashi, T.; Honda, T.; Nishiyama, N.; Kataoka, K.; Naito, S.; Kakizoe, T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br. J. Cancer 2005, 93, 678-687.
208. Franke, R.M.; Kosloske, A.M.; Lancaster, C.S.; Filipski, K.; Hu, C.; Zolk, O.; Mathijssen, R.H.; Sparreboom, A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-Acetyl-{beta}-D-Glucosaminidase. Clin. Cancer Res. 2010, 16, 4198-4206.
209. Sleijfer, D.T.; Offerman, J.J.G.; Mulder, N.H.; Verweij, M.; van der Hem, G.K.; Schraffordt Koops, H.; Meijer, S. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 1987, 60, 2823-2828.
210. Hanigan, M.H.; Gallagher, B.C.; Taylor, P.T., Jr.; Large, M.K. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res. 1994, 54, 5925-5929.
211. Hausheer, F.H.; Kochat, H.; Parker, A.R.; Ding, D.; Yao, S.; Hamilton, S.E.; Petluru, P.N.; Leverett, B.D.; Bain, S.H.; Saxe, J.D. New approaches to drug discovery and development: A mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother. Pharmacol. 2003, 52, 3-15.
212. Wu, Y.J.; Muldoon, L.L.; Neuwelt, E.A. The chemoprotective agent N-Acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J. Pharmacol. Exp. Ther. 2005, 312, 424-431.
213. Lynch, E.D.; Gu, R.; Pierce, C.; Kil, J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear. Res. 2005, 201, 81-89.
214. Karimi, G.; Ramezani, M.; Tahoonian, Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid. Based Complement. Alternat. Med. 2005, 2, 383-386.
215. Pan, H.; Mukhopadhyay, P.; Rajesh, M.; Patel, V.; Mukhopadhyay, B.; Gao, B.; Haskó, G.; Pacher, P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther. 2009, 328, 708-714.
216. Atessahin, A.; Yilmaz, S.; Karahan, I.; Ceribasi, A.O.; Karaoglu, A. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 2005, 212, 116-123.
217. Li, S.; Gokden, N.; Okusa, M.D.; Bhatt, R.; Portilla, D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am. J. Physiol. Renal Physiol. 2005, 289, F469-F480.
218. Tikoo, K.; Kumar, P.; Gupta, J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7,12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 2009, 9, 107.
219. Kang, K.P.; Kim, D.H.; Jung, Y.J.; Lee, A.S.; Lee, S.; Lee, S.Y.; Jang, K.Y.; Sung, M.J.; Park, S.K.; Kim, W. Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol. Dial. Transplant. 2009, 24, 3012-3020.
220. Carswell, E.A.; Old, L.J.; Kassel, R.L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 1975, 72, 3666-3670.
221. Kulbe, H.; Thompson, R.; Wilson, J.L.; Robinson, S.; Hagemann, T.; Fatah, R.; Gould, D.; Ayhan, A.; Balkwill, F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007, 67, 585-592.
222. Popivanova, B.K.; Kitamura, K.; Wu, Y.; Kondo, T.; Kagaya, T.; Kaneko, S.; Oshima, M.; Fujii, C.; Mukaida, N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008, 118, 560-570.
223. Waterson, A.; Bower, M. TNF and cancer: Good or bad? Cancer Ther. 2004, 2, 131-148.
224. Chen, R.; Alvero, A.B.; Silasi, D.A.; Steffensen, K.D.; Mor, G. Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008, 27, 225-233.
225. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M.C.; Ullrich, E.; Saulnier, P.; et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13, 1050-1059.